UCB enters into strategic partnerships in clinical development with PAREXEL and PRA
Strategic partnerships for focused global operational clinical development activities, using complementary strengths and expertise
Advertisement
UCB announced that it has entered into strategic partnerships with PAREXEL and PRA to drive UCB’s operational clinical development activities. The agreements are effective for all of UCB’s new clinical study programs on a global basis.
"We are pleased to announce these strategic partnerships as UCB aims to expand its global drug development activities, including in Asia. These partnerships represent long-term, win-win commitments to an outsourcing model focused on maximizing the effectiveness of each participant’s resources in clinical operations. These relationships are based upon integrity, trust and dedication to common goals", said Iris Loew-Friedrich, Executive Vice President and Chief Medical Officer of UCB. "Our strategic partnerships with PAREXEL and PRA will improve efficiency and cost effectiveness, as well as increase opportunity for innovation, collaboration, and the continuous improvement of quality and services – helping us to deliver new medicines to patients worldwide. By putting these new arrangements in place, PAREXEL and PRA essentially become integrated members of our study teams."
"As a leader in the strategic partnership model, we look forward to providing UCB with best practices to bolster the success of their development efforts. Leveraging our global resources and worldwide infrastructure, as well as the depth and breadth of our expertise, we look forward to working collaboratively with UCB to deliver customized, innovative solutions to achieve their goals," said Josef von Rickenbach, Chairman and Chief Executive Officer, PAREXEL International. "Through the partnership, UCB will receive the benefits of PAREXEL’s proven clinical processes through all phases of development, which are supported by its market-leading eClinical technology platform. UCB will also leverage PAREXEL’s consulting expertise in regulatory affairs and commercialization."
"We are pleased with UCB’s commitment to a true strategic partnership," noted Colin Shannon, President and CEO of PRA. "Working as an extension of UCB’s development team, we have the opportunity to execute trials in an innovative and transformational way. While our medical expertise includes significant experience in CNS indications, we also provide a full suite of services for clinical studies across all phases and therapeutic areas. With eClinical solutions, advanced technological tools and finely tuned systems we can achieve seamless delivery and operational transparency throughout our organization."
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
